New diabetes shot aims to rival semaglutide in blood sugar control
NCT ID NCT07653477
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study compares an experimental weekly injection called UBT251 to the approved drug semaglutide in adults with type 2 diabetes whose blood sugar is not well controlled by oral medications like metformin. The main goal is to see if UBT251 is at least as effective as semaglutide at lowering HbA1c over 36 weeks. The trial also tracks weight changes and safety. About 956 participants will receive one of three doses of UBT251 or semaglutide for up to 58 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UBT251 injection
What this could lead to
If successful, UBT251 could offer a new weekly injection option for type 2 diabetes that is as effective as semaglutide for lowering blood sugar and may also help with weight loss.
What could go wrong
This is a phase 3 trial, but UBT251 is still experimental. It may not prove as effective or safe as semaglutide, and side effects (like gastrointestinal issues) are possible. Results may not apply to all diabetes patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••